Blog
    Regulatory UpdateFor PhysiciansAugust 8, 2026

    FDA peptide status, BPC-157 safety, and FAERS signal analysis

    Review FDA Category 2 classifications for BPC-157 and TB-500, compounding eligibility updates, and emerging GLP-1 RA safety signals from the FAERS database.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    What is the current regulatory status of commonly used therapeutic peptides, and what safety signals have been identified through post-marketing surveillance and clinical trials?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and CJC-1295 are currently classified as FDA Category 2 bulk substances as of March 2026.
    • Compounding Eligibility: Several peptides previously nominated for 503A compounding have had nominations withdrawn or have been deemed ineligible due to safety risks.
    • Safety Signals: FAERS data for GLP-1 receptor agonists (GLP-1 RAs) indicate strong gastrointestinal signals and emerging concerns regarding ocular and pulmonary events.
    • Clinical Outcomes: Phase III data for approved GLP-1 RAs show significant weight loss (14.9%–22.5%) and MACE reduction (20%), while other peptides like Thymosin Alpha 1 have yielded negative results in recent sepsis trials.

    What the Research Shows

    Regulatory Compliance and Compounding Status

    As of March 2026, the FDA has classified several therapeutic peptides under Category 2 (Sept 2023), identifying them as substances with significant safety risks or lack of safety data, making them ineligible for routine compounding.

    BPC-157 is currently listed as a Category 2 bulk substance with no FDA approval. The FDA cites immunogenicity concerns and a lack of safety data. Warning letters have been issued to providers such as Tailor Made Compounding and Predator Nutrition regarding BPC-157.

    Thymosin Alpha-1, although approved in over 35 countries as Zadaxin, is not FDA-approved. It was moved to Category 2 in September 2023 and remains a substance of concern under interim policy despite a removal pending advisory review in September 2024.

    Similarly, TB-500 (Thymosin Beta-4) remains in Category 2 with no human exposure data and cited immunogenicity risks. Other peptides, including AOD-9604, Ipamorelin, Selank, and CJC-1295, had their 503A nominations withdrawn or were removed in September 2024. The FDA specifically noted safety issues such as increased heart rate for CJC-1295.

    FAERS Safety Signal Analysis

    Post-marketing surveillance via the FAERS database highlights significant adverse event (AE) trends for Semaglutide, with 187,757 total GLP-1 RA reports through 2023.

    • Gastrointestinal: Strong, dose-dependent signals exist for nausea, vomiting, and delayed gastric emptying. Acute pancreatitis is noted as a moderate signal, while intestinal obstruction (ileus) is an emerging signal recently added to post-marketing labels.
    • Hepatobiliary/Renal: Moderate signals for cholelithiasis and cholecystitis are associated with rapid weight loss. Acute kidney injury signals are detected, often secondary to GI-related dehydration.
    • Ocular/Pulmonary: An emerging signal for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) was identified (96 cases through Dec 2024), leading to a formal EMA review in January 2025. Pulmonary aspiration is also an emerging signal, resulting in label updates for Ozempic in 2025 due to risks during general anesthesia.

    Clinical Trial Data

    Clinical evidence for Semaglutide (STEP 1) and Tirzepatide (SURMOUNT-1) demonstrates weight loss of 14.9% and 22.5%, respectively. The SELECT trial further established a 20% reduction in Major Adverse Cardiovascular Events (MACE) for Semaglutide. Retatrutide, a Phase II candidate, demonstrated 24.2% weight loss at 12mg, with Phase III trials (TRIUMPH-3) currently active.

    Conversely, Thymosin Alpha 1 failed to show a reduction in mortality in the Phase III TESTS trial for sepsis (PMID: 39814420).

    Mechanism

    The mechanism of action for specific peptides in this data set focuses on their clinical effects. Tesamorelin is associated with an 18% reduction in Visceral Adipose Tissue (VAT). Semaglutide and Tirzepatide facilitate weight loss and cardiovascular risk reduction, while their mechanism of delayed gastric emptying is a noted contributor to pulmonary aspiration risk and altered oral medication absorption.

    Limitations of the Evidence

    A significant limitation is the lack of human exposure and safety data for several peptides currently in regulatory Category 2, such as TB-500 and BPC-157. While FAERS data provides signals for Semaglutide, current data on suicidal ideation do not support a higher risk compared to background rates, despite FDA monitoring requirements. The status of Thymosin Alpha 1 remains in flux pending further advisory review. Many peptides, such as Selank and Semax, have approvals in Russia but lack corresponding FDA clinical trial data for their noted indications.

    Clinical Takeaway

    Physicians should note that several widely discussed peptides (BPC-157, TB-500, CJC-1295) are currently classified as FDA Category 2 substances due to immunogenicity and safety concerns, rendering them ineligible for routine compounding. While GLP-1 RAs show robust efficacy in weight loss and MACE reduction, they are associated with strong gastrointestinal signals and emerging ocular and pulmonary risks that require clinical monitoring, particularly in surgical or dehydrated contexts.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2).
    • FAERS Safety Signal Records (Semaglutide 2023-2025).
    • Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, NCT02867267.

    Referenced Peptides

    bpc 157semaglutidethymosin alpha 1tb 500cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.